Engineered immune cells take on Hard-to-Treat blood cancer
NCT ID NCT07248176
First seen Jan 04, 2026 · Last updated May 23, 2026 · Updated 20 times
Summary
This early study tests a new treatment called BCMA-UCART, which uses donor immune cells engineered to find and attack a protein (BCMA) on multiple myeloma cells. It is for adults whose cancer has returned or not responded to at least two prior treatments. The main goals are to check safety and see if the therapy can control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghi Tongji Hospital (Tongji Hospital of Tongji University)
RECRUITINGShanghai, 620000, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.